Investigational Drug Information for CC-486
What is the development status for investigational drug CC-486?
CC-486 is an investigational drug.
There have been 48 clinical trials for CC-486.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 26th 2013.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, Acute, and Lymphoma. The leading clinical trial sponsors are Celgene, Celgene Corporation, and National Cancer Institute (NCI).
Summary for CC-486
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 4,051 |
| Clinical Trial Progress | Phase 2 (2013-04-26) |
| Vendors | 72 |
Recent Clinical Trials for CC-486
| Title | Sponsor | Phase |
|---|---|---|
| Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia | Acute Leukemia French Association | Phase 2 |
| Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia | French Innovative Leukemia Organisation | Phase 2 |
| Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients | Bristol-Myers Squibb | Phase 2 |
Clinical Trial Summary for CC-486
Top disease conditions for CC-486
Top clinical trial sponsors for CC-486
US Patents for CC-486
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
CC-486 (Oral Azacitidine) Development Update and Market Projection
CC-486, marketed as Onureg by Bristol Myers Squibb, is an oral azacitidine formulation approved for maintenance treatment of adults with acute myeloid leukemia (AML) who achieved complete remission or complete remission with incomplete blood-count recovery after intensive induction chemotherapy and cannot complete intensive curative therapy. The drug remains commercially relevant because it is the first FDA-approved oral maintenance HMA for this AML population, but its addressable market is limited by strict eligibility criteria and competition from venetoclax-based regimens, injectable azacitidine, clinical trials and post-transplant strategies.
The base-case outlook is for a mature global Onureg market of approximately $500 million to $750 million annually through 2027, with U.S. sales contributing the majority. Patent protection and orphan-drug exclusivity delay conventional generic erosion, although the commercial risk is more likely to emerge from treatment substitution and competing AML maintenance regimens than from an immediate generic launch.
What is CC-486 and how is it different from injectable azacitidine?
CC-486 is the oral formulation of azacitidine, a cytidine nucleoside analog and hypomethylating agent. It is not interchangeable with injectable Vidaza.
| Attribute | CC-486 / Onureg | Injectable azacitidine / Vidaza |
|---|---|---|
| Active ingredient | Azacitidine | Azacitidine |
| Administration | Oral tablet | Subcutaneous or intravenous |
| FDA approval | September 2020 | 2004 |
| Principal use | AML maintenance after remission | MDS and AML treatment, depending on regimen |
| Standard Onureg regimen | 300 mg orally on Days 1-14 of each 28-day cycle | Weight- or body-surface-area-based injection schedules |
| FDA application | NDA 212860 | NDA 050794 |
| Primary commercial holder | Bristol Myers Squibb through Celgene acquisition | Generic and branded suppliers |
| Clinical positioning | Post-remission maintenance | Active disease treatment and lower-intensity therapy |
The oral formulation was developed to provide prolonged exposure across a 28-day treatment cycle. The pharmacokinetic and pharmacodynamic profile differs from injectable azacitidine, so clinicians cannot substitute the two products on a milligram-for-milligram basis.
What clinical evidence supports Onureg?
The approval was based primarily on the phase 3 QUAZAR AML-001 study, which enrolled adults with AML in first remission after intensive chemotherapy who were not candidates for hematopoietic stem-cell transplantation or additional intensive chemotherapy.
The study showed:
| Endpoint | CC-486 | Placebo | Result |
|---|---|---|---|
| Median overall survival | 24.7 months | 14.8 months | Hazard ratio 0.69 |
| Median relapse-free survival | 10.2 months | 4.8 months | Hazard ratio 0.65 |
| Two-year overall survival | Approximately 51% | Approximately 37% | Superior with CC-486 |
The trial established a clinically meaningful maintenance benefit, with the strongest commercial implication in older AML patients who achieve remission but remain at high risk of relapse and cannot proceed to transplant. The results were published in the New England Journal of Medicine in 2020.[1]
Common adverse reactions include nausea, vomiting, diarrhea, neutropenia, thrombocytopenia, anemia and febrile neutropenia. The label requires antiemetic prophylaxis and treatment interruption or dose modification for hematologic and gastrointestinal toxicity.[2]
What is the current FDA and international regulatory status of CC-486?
The FDA approved Onureg on September 1, 2020, under NDA 212860. The approved indication is limited to AML patients in first or subsequent complete remission or complete remission with incomplete blood-count recovery following intensive induction chemotherapy who are unable to complete intensive curative therapy.[2]
The European Commission granted marketing authorization for Onureg in 2021 for maintenance treatment of adult AML patients who achieved complete remission or complete remission with incomplete blood-count recovery after intensive induction chemotherapy and are not candidates for hematopoietic stem-cell transplantation.[3]
FDA regulatory milestones
| Milestone | Date |
|---|---|
| Phase 3 QUAZAR AML-001 results | 2020 |
| FDA approval | September 1, 2020 |
| Initial U.S. maintenance indication | 2020 |
| European authorization | 2021 |
| Recommended dose | 300 mg orally on Days 1-14 of each 28-day cycle |
CC-486 is a small-molecule drug. Biosimilar regulation does not apply. Any follow-on competitor would generally pursue an abbreviated new drug application, subject to formulation, bioequivalence, labeling and patent-certification requirements.
What patents protect CC-486 and when could generic competition begin?
The Onureg estate is based on oral azacitidine formulation and use patents rather than the basic azacitidine molecule, which has long been off patent.
A representative U.S. formulation patent family associated with oral azacitidine is U.S. Patent No. 10,183,020, assigned to Celgene. The family covers oral azacitidine formulations and related pharmaceutical compositions. Continuation and related applications may create overlapping claim scope around formulation, dosage, treatment schedules and use in AML maintenance.[4]
| Protection category | Relevance to Onureg | Estimated U.S. protection profile |
|---|---|---|
| Azacitidine active ingredient | No meaningful current exclusivity | Expired or long expired |
| Oral formulation patents | Core protection for Onureg tablets | Into the mid-2030s for representative families |
| AML maintenance method patents | Protect treatment use and regimen claims | Patent-specific; may extend beyond initial approval |
| Orphan-drug exclusivity | Potential protection for the approved AML population | Approximately seven years from U.S. approval if applicable |
| Pediatric exclusivity | No established commercial impact identified | Patent- and FDA-record-dependent |
| Patent-term adjustment or extension | Could alter individual expiration dates | Requires review of the issued patent record |
The principal commercial protection period is therefore longer than the basic azacitidine molecule’s life cycle. The relevant generic-entry date depends on which patents remain listed in the FDA Orange Book, whether a generic applicant files Paragraph IV certifications, whether BMS sues within the statutory period and whether the asserted claims survive litigation.
What is the Orange Book status of Onureg?
Onureg is listed under FDA NDA 212860. The FDA Orange Book remains the controlling source for listed patents, pediatric exclusivity and therapeutic-equivalence information.[5]
An ANDA applicant may certify that a listed patent is expired, will expire on a specified date, is not infringed or is invalid. A Paragraph IV certification can trigger patent litigation and, if suit is filed within the statutory period, a stay of ANDA approval for up to 30 months, subject to court decisions and regulatory exceptions.
The likely U.S. generic scenario is:
- No meaningful generic entry during the core patent term.
- Paragraph IV activity before expiration if the commercial opportunity is large enough.
- Litigation focused on oral formulation claims, treatment schedules and the scope of the approved AML-maintenance indication.
- Potential launch after patent expiry, settlement, invalidation or a license.
A generic could also seek a narrower label that omits patented AML-maintenance uses. That strategy would depend on the remaining patent claims and FDA labeling requirements.
Are there active development programs for CC-486?
The major development milestone has already occurred: conversion of CC-486 from an investigational oral HMA into an approved AML maintenance product. The current development opportunity is primarily lifecycle management rather than a new molecular entity.
Potential development directions include:
Post-transplant maintenance
Maintenance after allogeneic stem-cell transplantation is a logical clinical use because relapse remains a major cause of treatment failure. However, post-transplant patients have different tolerability, immunologic and graft-versus-host disease considerations. A successful trial would need to demonstrate benefit without materially increasing cytopenias, infection risk or graft complications.
Combination with venetoclax
Venetoclax plus azacitidine is a major lower-intensity frontline AML regimen. Combining oral azacitidine with venetoclax could improve convenience but would face substantial safety and development barriers, including prolonged cytopenias, infection risk and the need to distinguish maintenance from active-disease treatment.
Maintenance after lower-intensity induction
Patients treated with venetoclax-based therapy may create a larger maintenance population than the original QUAZAR AML-001 group. The clinical value of switching from injectable azacitidine plus venetoclax to CC-486 after remission remains dependent on prospective evidence.
Myelodysplastic syndromes
Oral azacitidine has development potential in MDS, but it competes with oral decitabine/cedazuridine, marketed as Inqovi. A separate MDS indication would require evidence that CC-486 provides benefit beyond existing HMA options and does not create clinically unacceptable gastrointestinal or hematologic toxicity.
How strong is the CC-486 patent estate?
The estate is moderately strong from a commercial perspective because it combines several protection layers:
- A branded oral formulation differentiated from older injectable azacitidine.
- FDA approval for a defined AML maintenance population.
- Clinical evidence supporting a specific post-remission schedule.
- Potential orphan-drug exclusivity for the AML indication.
- Formulation and method-of-use claims that can complicate a simple generic substitution.
Its weaknesses are equally clear. Azacitidine is an old active ingredient, so composition-of-matter protection does not support the product. Competitors can use alternative formulations, different dosing approaches or injectable regimens. The commercial value of method-of-use patents also depends on whether physicians prescribe the drug for the patented indication and whether a generic can enter with a restricted label.
The most important patent risk is not basic molecule invalidity. It is claim construction and obviousness challenges directed at the oral formulation, treatment duration, dosing schedule and relationship between oral and injectable azacitidine.
Which companies challenge Onureg commercially?
No biosimilar company can challenge Onureg because biosimilar law applies to biologics, not small molecules. The relevant competitive groups are generic manufacturers, AML drug developers and companies marketing alternative maintenance or lower-intensity regimens.
| Competitor | Product or strategy | Competitive threat |
|---|---|---|
| Generic azacitidine manufacturers | Injectable azacitidine | Lower-cost alternative, but not therapeutically interchangeable |
| Taiho and licensing partners | Inqovi, oral decitabine/cedazuridine | Competes for oral HMA use, especially in MDS |
| AbbVie and Genentech | Venetoclax combinations | May reduce the future need for standalone maintenance |
| Academic and commercial developers | Post-transplant and targeted maintenance | Could narrow the eligible Onureg population |
| Generic ANDA applicants | Future oral azacitidine products | Direct price competition after patent or settlement resolution |
The principal competitive threat is therapeutic substitution. Onureg’s opportunity depends on physicians continuing to use HMA maintenance after remission rather than moving patients to transplant, targeted maintenance, clinical trials or continued venetoclax-based treatment.
What is the market size and revenue projection for Onureg?
The addressable population is narrower than the total AML market. A practical market model begins with:
- Annual AML incidence.
- Patients receiving intensive induction.
- Patients achieving remission.
- Patients unable to proceed to transplant or additional intensive chemotherapy.
- Patients suitable for oral maintenance.
- Persistence over multiple 28-day cycles.
The U.S. opportunity is supported by high treatment cost, a large academic AML network and concentration of prescribing among hematology specialists. Europe and Japan add meaningful volume, but pricing and reimbursement are more restrictive.
Base-case market projection
| Year | Estimated global net sales | Market condition |
|---|---|---|
| 2024 | $350 million-$500 million | Established adoption in AML maintenance |
| 2025 | $400 million-$575 million | Continued penetration and international reimbursement |
| 2026 | $450 million-$650 million | Mature uptake, limited label expansion |
| 2027 | $500 million-$750 million | Peak or near-peak commercial period |
| 2028-2030 | $350 million-$650 million | Range depends on generic timing and competing regimens |
These figures are an analyst scenario rather than Bristol Myers Squibb guidance. The base case assumes continued use in the FDA-approved population, moderate international uptake and no rapid displacement by a competing maintenance standard.
Scenario analysis
| Scenario | 2027 global sales | Main drivers |
|---|---|---|
| Downside | $250 million-$400 million | Faster therapeutic substitution, weak persistence, early generic settlement |
| Base case | $500 million-$750 million | Stable AML maintenance use and gradual international growth |
| Upside | $800 million-$1.0 billion | Expanded maintenance use, positive post-transplant data or broader combination adoption |
The upside case requires a clinically validated expansion beyond the original QUAZAR AML-001 population. Without an expanded label or new evidence, the market is more likely to plateau than compound rapidly.
What generic launch risks exist for CC-486?
The earliest realistic direct-generic risk is linked to the expiration or settlement of the principal oral formulation and method-of-use patents, not to the expiration of azacitidine itself.
A first generic launch would likely produce a sharp price decline because:
- The product has one active ingredient.
- Manufacturing is less complex than biologic production.
- Injectable azacitidine provides a reference product and established HMA supply chain.
- Payers can encourage substitution once therapeutic equivalence is established.
However, generic launch may not immediately eliminate branded revenue. Onureg has a defined maintenance indication, physician familiarity and oral convenience. BMS could retain a portion of sales through contracting, patient support and formulary positioning.
The most material downside event would be a successful Paragraph IV challenge followed by a first-filer launch. A later authorized generic or settlement would produce a slower erosion curve but still compress net price.
How does CC-486 compare with Inqovi and injectable azacitidine?
| Factor | Onureg | Inqovi | Injectable azacitidine |
|---|---|---|---|
| Active ingredient | Azacitidine | Decitabine plus cedazuridine | Azacitidine |
| Main approved use | AML maintenance | MDS and CMML | MDS and related indications |
| Oral administration | Yes | Yes | No |
| AML maintenance evidence | Strong phase 3 evidence | Not equivalent to QUAZAR evidence | No direct oral-maintenance equivalence |
| Main advantage | Maintenance efficacy and convenience | Oral delivery with decitabine exposure | Established use and lower-cost alternatives |
| Main limitation | Narrow indication and patent exposure | Smaller commercial base and different evidence | Administration burden and schedule complexity |
Onureg has the strongest direct evidence for AML remission maintenance. Inqovi is a closer oral-HMA competitor in MDS than in the approved AML maintenance market. Injectable azacitidine remains the main price and treatment-pathway comparator but cannot be treated as a direct generic substitute for Onureg.
What licensing and corporate transactions affect CC-486?
CC-486 originated within Celgene and became part of Bristol Myers Squibb through BMS’s acquisition of Celgene, completed in 2019. BMS therefore controls the principal commercial, regulatory and intellectual-property position in the United States.
The acquisition increased BMS’s hematology portfolio and placed Onureg alongside Revlimid, Pomalyst, Empliciti and other blood-cancer assets. No separate licensing transaction is required to explain current U.S. ownership of Onureg. International commercialization may involve regional distribution or commercialization arrangements, but BMS remains the central holder of the product’s global development and brand strategy.
What is the investment and commercial outlook for CC-486?
Onureg is a durable specialty-hematology product rather than a high-growth platform asset. Its value rests on recurring maintenance treatment, oral convenience and survival data. The commercial ceiling is constrained by the size of the remission-maintenance population and the absence of a broad AML treatment indication.
Revenue exposure is material to the Onureg franchise but modest relative to Bristol Myers Squibb’s overall portfolio. The principal valuation variables are:
- Duration of patent and orphan exclusivity.
- Paragraph IV filing and litigation timing.
- Use after venetoclax-based induction.
- Post-transplant maintenance data.
- Treatment persistence and discontinuation rates.
- International reimbursement.
- Competition from oral decitabine and alternative maintenance approaches.
The most probable outcome is a stable specialty product with peak global sales below $1 billion, followed by gradual erosion once direct oral generic competition becomes legally and commercially feasible.
Key Takeaways
- CC-486 is Onureg, an oral azacitidine tablet owned and marketed by Bristol Myers Squibb.
- FDA approval occurred in September 2020 for AML maintenance after intensive induction chemotherapy.
- QUAZAR AML-001 showed median overall survival of 24.7 months with Onureg versus 14.8 months with placebo.
- The product is not interchangeable with injectable azacitidine.
- The core commercial protection comes from oral formulation, dosing and method-of-use patents, with representative protection extending into the mid-2030s.
- Biosimilar risk does not apply because Onureg is a small molecule.
- Paragraph IV litigation is the principal direct-generic risk.
- The base-case global sales outlook is approximately $500 million to $750 million by 2027.
- The largest commercial threat is therapeutic substitution by venetoclax-based, post-transplant or other maintenance strategies.
- Expansion into post-transplant maintenance or broader remission-maintenance populations could materially improve the revenue profile.
FAQs
Is CC-486 the same drug as Vidaza?
No. Both contain azacitidine, but CC-486 is an oral formulation with a distinct pharmacokinetic profile and approved maintenance regimen. It should not be substituted for injectable Vidaza on a milligram-for-milligram basis.
Can Onureg be used with venetoclax?
Onureg may be studied or used in clinical practice in combination-based treatment strategies, but the FDA-approved Onureg indication is post-remission AML maintenance. Combination use must follow the applicable label, clinical evidence and treatment protocol.
Does Onureg have orphan-drug exclusivity?
Onureg was developed for AML, a rare disease category. The duration and scope of any orphan exclusivity must be determined from the FDA exclusivity record for NDA 212860 and the specific approved indication.
What is the standard Onureg dosing schedule?
The labeled regimen is 300 mg orally once daily on Days 1 through 14 of each 28-day cycle, with antiemetic prophylaxis and dose modifications for toxicity.
Will a generic version of Onureg automatically replace injectable azacitidine?
No. A generic oral azacitidine product would compete directly with Onureg, while injectable azacitidine remains a different dosage form with different administration, exposure and labeling. Therapeutic interchangeability would depend on FDA approval and payer policy.
References
-
Wei, A. H., Döhner, H., Pocok, C., et al. (2020). Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. New England Journal of Medicine, 383(26), 2526-2537.
-
U.S. Food and Drug Administration. (2020). Onureg (azacitidine) tablets: Prescribing information. FDA.
-
European Medicines Agency. (2021). Onureg: EPAR product information. EMA.
-
U.S. Patent No. 10,183,020. (2019). Oral formulations of azacitidine. United States Patent and Trademark Office.
-
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book, NDA 212860. FDA.
-
Bristol Myers Squibb. (2024). 2023 annual report and Form 10-K. Bristol Myers Squibb.
More… ↓
